Insulin Glargine v Rosiglitazone as add-on Therapy in Patients Failing Sulfonylurea and Metformin Combination Therapy

INCLUSION CRITERIA: * Diagnosis of type 2 diabetes mellitus for at least one year; * Continuous treatment with at least half maximally labeled dose of a sulfonylurea and at least 1000 mg metformin daily for at least three months ; * Glycated hemoglobin between 7.5 and 11 % units, inclusive; * Willingness to accept, and ability to inject insulin glargine therapy EXCLUSION CRITERIA: * Stroke, MI, coronary artery bypass graft, percutaneous transluminal coronary angioplasty or angina pectoris within the last 12 months; * Congestive heart failure requiring pharmacological treatment; * Serum creatinine \> 1.5 mg/dl for males, or \> 1.4 mg/dl for females; * Acute or chronic metabolic acidosis, including diabetic ketoacidosis; * Planned radiological examinations requiring administration of contrasting agents; * Clinical evidence of active liver disease, or serum ALT 2.5 times the upper limit of the normal range; * History of hypoglycemia unawareness; * Pregnancy or lactation; * Failure to use adequate contraception (women of current reproductive potential only); * Known hypersensitivity to insulin glargine, rosiglitazone or any of the components of insulin glargine rosiglitazone; * BMI \>25 kg/m2; * Malignancy except basal cell carcinoma within the last five years; * History of substance or alcohol abuse within last two years, or current addiction to substance or alcohol abuse; * Any disease or condition that in the opinion of the investigator and/or sponsor may interfere with completion of the study; * Incapability to comply with study procedures